SironRX is a spinoff of the privately-held biotechnology company Juventas Therapeutics which licensed the drug’s intellectual property from Cleveland Clinic in 2007.
SironRX’s lead drug JVS-100 contains an engineered version of a naturally occurring molecular factor called Stromal cell-Derived Factor-1 (SDF-1) that promotes tissue repair, reduces healing time, scarring, and possible complications.
SironRX will use the funding to work towards initiating a Phase II clinical trial evaluating the potential of JVS-100 to promote wound repair and prevent scarring in post-surgical wounds.
This investment represents JumpStart Ventures’ 74th investment in its 53rd company and SironRX is one of 35 Cleveland Clinic spinoffs that have raised more than $450m in equity financing.